The purpose of this study is to examine the relationship between loading dose and adherence to Orencia.

Inclusion Criteria:

• Patients will be identified based on the presence of first infusion claim during study period for Orencia
• At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date
• Patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below
• Patients with a minimum of 3 infusion claims for Orencia
• Only those patients will be included whose first 3 infusion claims occur within 84 days

Exclusion Criteria:

• Patients less than 18 years of age at index date.
• One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period
• Patients who switch between biologics within their first three infusion claims
• Restarts, defined as those patients who go back on Orencia after a gap of 42 days
• Patients who are on other biologics at the same time as Orencia

Commercial health plan members